Voyager Therapeutics’ (VYGR) Buy Rating Reaffirmed at Cowen

Cowen reiterated their buy rating on shares of Voyager Therapeutics (NASDAQ:VYGR) in a report issued on Tuesday morning, AnalystRatings.com reports.

A number of other analysts have also recently issued reports on the stock. Wedbush raised their target price on shares of Voyager Therapeutics from $27.00 to $36.00 and gave the stock an outperform rating in a research note on Tuesday, June 18th. Zacks Investment Research upgraded shares of Voyager Therapeutics from a hold rating to a buy rating and set a $19.00 target price for the company in a research note on Saturday, October 12th. ValuEngine cut shares of Voyager Therapeutics from a strong-buy rating to a buy rating in a research note on Wednesday, September 4th. BidaskClub cut shares of Voyager Therapeutics from a sell rating to a strong sell rating in a research note on Tuesday, August 27th. Finally, Nomura restated a buy rating and set a $37.00 target price on shares of Voyager Therapeutics in a research note on Tuesday, August 13th. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and nine have assigned a buy rating to the company’s stock. The company presently has an average rating of Buy and an average price target of $27.63.

VYGR stock traded down $0.52 during trading hours on Tuesday, reaching $14.89. The stock had a trading volume of 23,223 shares, compared to its average volume of 433,697. The stock has a market capitalization of $532.90 million, a PE ratio of -5.41 and a beta of 2.61. The stock has a 50-day simple moving average of $16.86 and a 200 day simple moving average of $21.41. Voyager Therapeutics has a fifty-two week low of $7.76 and a fifty-two week high of $28.79.

Voyager Therapeutics (NASDAQ:VYGR) last posted its earnings results on Friday, August 9th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $1.17. The company had revenue of $46.09 million during the quarter, compared to analysts’ expectations of $5.25 million. Voyager Therapeutics had a negative net margin of 106.23% and a negative return on equity of 71.08%. As a group, sell-side analysts predict that Voyager Therapeutics will post -1.95 earnings per share for the current fiscal year.

A number of large investors have recently added to or reduced their stakes in VYGR. Clearbridge Investments LLC increased its position in Voyager Therapeutics by 93,030.6% during the first quarter. Clearbridge Investments LLC now owns 379,973 shares of the company’s stock worth $7,273,000 after acquiring an additional 379,565 shares during the period. Convergence Investment Partners LLC acquired a new stake in Voyager Therapeutics during the 2nd quarter worth approximately $108,000. First Quadrant L P CA acquired a new stake in Voyager Therapeutics during the 2nd quarter worth approximately $86,000. Strs Ohio acquired a new stake in Voyager Therapeutics during the 2nd quarter worth approximately $574,000. Finally, Steward Partners Investment Advisory LLC acquired a new stake in Voyager Therapeutics during the 2nd quarter worth approximately $27,000. 78.49% of the stock is currently owned by institutional investors and hedge funds.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease.

See Also: Stock Split

Analyst Recommendations for Voyager Therapeutics (NASDAQ:VYGR)

Receive News & Ratings for Voyager Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Voyager Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.